- Home
- SSL vs ACLX Comparison
SSL vs ACLX Comparison
Compare SSL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSL | ACLX |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SSL | ACLX |
|---|---|---|
| Price | $6.00 | $69.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $115.50 |
| AVG Volume (30 Days) | 945.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $14,028,282,389.00 | $35,898,000.00 |
| Revenue This Year | $1.17 | N/A |
| Revenue Next Year | $6.50 | $302.49 |
| P/E Ratio | $10.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.78 | $47.86 |
| 52 Week High | $7.39 | $94.07 |
Technical Indicators
Market Signals| Indicator | SSL | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 33.01 |
| Support Level | $6.27 | $66.00 |
| Resistance Level | $6.46 | $75.03 |
| Average True Range (ATR) | 0.15 | 5.23 |
| MACD | -0.11 | -1.69 |
| Stochastic Oscillator | 2.11 | 12.96 |
Price Performance
Historical ComparisonAbout SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.